HC Wainwright & Co. Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has initiated coverage on Calidi Biotherapeutics (AMEX:CLDI) with a Buy rating and set a price target of $11.
November 22, 2023 | 11:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calidi Biotherapeutics received a Buy rating from HC Wainwright & Co. with a price target of $11, indicating a positive outlook from the analyst.
The initiation of coverage by HC Wainwright & Co. with a Buy rating and a price target that is potentially higher than the current trading price can be a strong positive signal to investors, suggesting a bullish outlook for CLDI's stock in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100